Clinical trial · Observational
Cell Samples From Patients With Leukemia
Xenotransplantation of Primary Leukemia Samples Into Zebrafish
NCT01395628CI-TRIAL-00022308completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about cancer and the development of drug resistance in patients. It may also help doctors find better ways to treat cancer. PURPOSE: This research trial is studying samples from patients with leukemia.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Leukemia | Leukemia | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (5)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| cell proliferation assay | Other | — | UNRESOLVED |
| fluorescence activated cell sorting | Other | — | UNRESOLVED |
| in vitro sensitivity-directed chemotherapy | Drug | — | UNRESOLVED |
| laboratory biomarker analysis | Other | — | UNRESOLVED |
| microscopy | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (3)
- measure
- Primary human leukemia samples capable to survive and proliferate in the zebrafish embryo
- measure
- In vivo confirmation of anti-proliferative or toxic effects of known chemotherapeutic agents on the transplanted cells
- measure
- Effects of novel anticancer drugs and/or their combinations on individual samples
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 30 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Samples of blood and tissue cells from patients diagnosed with myeloid disease including the following subtypes: * Chronic phase chronic myeloid leukemia (CML), to complement initial studies in the K562 CML cell line * Acute promyelocytic leukemia (APL), to complement initial studies in the NB4 APL cell line * Acute myeloid leukemia (AML) expressing the t(8;21)(q22;q22) translocation, which occurs in approximately 12% of pediatric AML and is associated with good prognosis * AML expressing 5q- or monosomy 7, associated with a poor prognosis * AML expressing the fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD), associated with a poor prognosis PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * Not specified
References
Publications (0)
Data not yet available
No reference posted for this study.